IP Library Granted Patent US 8,202,902
Granted Patent B2
US 8,202,902 · App. 12/270,374 · Granted Jun 19, 2012

Bivalent SMAC mimetics and the uses thereof

Assignee: The Regents of the University of Michigan
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,202,902
App. No.
12/270,374
Granted
Jun 19, 2012
Kind
B2
Abstract

The invention relates to bivalent mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.

Claims (20)

1. The compound having formula XIII:

wherein:

D″ is (CR 1 R 2 ) n —R 5c —(CR 3 R 4 ) m ;

J is selected from the group consisting of optionally substituted alkylenyl and (CR 1 R 2 ) p —R 5b —(CR 3 R 4 ) q ;

T is selected from the group consisting of C═O, C═S, C═NR 1 , S, O, NR 1 , CR 1 R 2 , optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl;

U is selected from the group consisting of hydrogen, NR 1 R 2 , OR 1 , SR 1 , optionally substituted alkyl and optionally substituted aryl;

n, m, p and q are independently selected from 0-5;

each R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl;

R 5c is selected from the group consisting of NR 1 , NCOR 8 and NCO 2 R 8 ;

R 1a and R 2a are independently selected from the group consisting of hydrogen, hydroxy, azido, optionally substituted alkyl, optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl;

R 5b is selected from the group consisting of O, S, NR 1 , CR 1 R 2 , C═O, C═S and C═NR 1 ;

R 7 is selected from the group consisting of hydrogen, CO 2 R 7a and COCH(R 7b )N(R 7c )CO 2 R 2a ;

R 7a is selected from the group consisting of optionally substituted alkyl, optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl;

R 7b is optionally substituted C 1-3 alkyl;

R 7c is selected from the group consisting of hydrogen and optionally substituted alkyl;

and,

R 8 is selected from the group consisting of optionally substituted alkyl, optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl.

2. The compound of claim 1 , wherein R 7a is t-butyl.

3. The compound of claim 1 , wherein n is 1, m is 2, R 5c is NCO 2 R 8 and R 8 is benzyl.

4. The compound of claim 1 , selected from the group consisting of:

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 27, 2011
From: UNIVERSITY OF MICHIGAN
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 025704/0921 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2009
From: WANG, SHAOMENG; SUN, HAIYING; QIN, DONGGUANG; NIKOLOVSKA-COLESKA, ZANETA; LU, JIANFENG; QIU, SU; PENG, YUEFENG; CAI, QIAN
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 022083/0772 →
Continuity (4)
Continuation In Part 11800220 · May 4, 2007
Provisional Application 60923415 · Apr 13, 2007
Provisional Application 60798018 · May 5, 2006
Related Publication 20090123480A1 · May 14, 2009